Cirrhosis News and Research RSS Feed - Cirrhosis News and Research

Cirrhosis is a condition in which the liver slowly deteriorates and malfunctions due to chronic injury. Scar tissue replaces healthy liver tissue, partially blocking the flow of blood through the liver. Scarring also impairs the liver’s ability to control infections, remove bacteria and toxins from the blood, process nutrients, hormones and drugs, make proteins that regulate blood clotting and produce bile to help absorb fats—including cholesterol—and fat-soluble vitamins.
Study: African Americans who moved from the South during Great Migration face shorter life expectancy

Study: African Americans who moved from the South during Great Migration face shorter life expectancy

Millions of African Americans moved from the South in the early 20th century to seek better job opportunities and higher wages, but a new study on the historic Great Migration shows that with improved economic conditions came a greater risk of mortality. [More]
ABIVAX doses first patient in ABX203 Phase IIb/III trial for treatment of chronic hepatitis B

ABIVAX doses first patient in ABX203 Phase IIb/III trial for treatment of chronic hepatitis B

ABIVAX, a clinical stage biotech company developing and commercialising anti-viral compounds and human vaccines, today announced that it has dosed in New Zealand the first patient in a Phase IIb/III clinical trial of ABX203 which is taking place in several countries of the Asia-Pacific region. [More]
Scientists detect new molecule that contributes to development of liver fibrosis

Scientists detect new molecule that contributes to development of liver fibrosis

Liver fibrosis, which is the progressive formation of scar tissue in the liver, is a massive medical problem. An estimated ten percent of the population is affected by liver fibrosis or its corresponding later stage, liver cirrhosis. A variety of causes can lead to liver fibrosis, the most widely recognized ones being alcohol consumption and virus-induced chronic liver inflammation. [More]
‘Most’ cirrhotic HBV patients benefit from adding adefovir to lamivudine

‘Most’ cirrhotic HBV patients benefit from adding adefovir to lamivudine

Response-guided addition of adefovir to lamivudine-based therapy not only maintains long-term viral suppression in Chinese chronic hepatitis B patients with compensated liver cirrhosis, research suggests, but also improves liver function. [More]
Betaretrovirus may infect patients with primary biliary cirrhosis

Betaretrovirus may infect patients with primary biliary cirrhosis

In a new study published in Alimentary Pharmacology & Therapeutics, researchers at the University of Alberta's Faculty of Medicine & Dentistry have shown that a betaretrovirus which resembles a mouse mammary tumor virus infects patients with the rare liver disease, primary biliary cirrhosis (PBC). [More]
Possible cause of liver disease identified in adolescents with cystic fibrosis

Possible cause of liver disease identified in adolescents with cystic fibrosis

A professor at the University of Colorado School of Medicine at the Anschutz Medical Campus and his colleagues have found a possible cause of liver disease in adolescents with cystic fibrosis. [More]
SLU researchers halt fatty liver disease in animal model

SLU researchers halt fatty liver disease in animal model

Doctors believe that up to 30 percent of the U.S. population may have fat accumulation in the liver, known as non-alcoholic fatty liver disease (NAFLD), that can lead to a range of damaging health consequences. [More]
Rutgers patient gets second chance at life following liver transplant

Rutgers patient gets second chance at life following liver transplant

Mati Muñoz is 65 years old - filled with the enthusiastic energy that comes with a second chance at life. A decade ago, says Muñoz, who lives in Woodbridge Township, N.J., her liver was being destroyed by hepatitis C, a viral disease she believes she contracted as a girl in her native Cuba from a poorly sterilized needle used in a medical procedure. [More]
AbbVie submits NDA in Japan for investigational, all-oral treatment of patients with chronic HCV infection

AbbVie submits NDA in Japan for investigational, all-oral treatment of patients with chronic HCV infection

AbbVie (NYSE: ABBV) submitted a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare (MHLW) seeking approval for the company's investigational, all-oral, ribavirin (RBV) and interferon (IFN)-free, 12-week, two direct-acting antiviral treatment of ombitasvir/paritaprevir/ritonavir (OBV/PTV/r), dosed once daily. [More]
GI Society releases video to spread awareness about hepatitis C

GI Society releases video to spread awareness about hepatitis C

As many as 350,000 Canadians could be suffering with hepatitis C, many of whom are unaware that they are infected, thus continuing to spread the virus. Although there is a vaccine to prevent the spread of the hepatitis A and hepatitis B viruses, there is no vaccine for hepatitis C. The good news is that with new treatments, hepatitis C is now a curable disease. [More]
Regulus Therapeutics reports top-line results from RG-101 clinical study for HCV treatment

Regulus Therapeutics reports top-line results from RG-101 clinical study for HCV treatment

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced top-line results from the 4 mg/kg cohort and additional results from the 2 mg/kg cohort in a completed clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting microRNA-122 ("miR-122"), for the treatment of hepatitis C virus infection ("HCV"). [More]
New findings could pave way to develop drug therapies for necrosis-related diseases

New findings could pave way to develop drug therapies for necrosis-related diseases

Strokes, heart attacks and traumatic brain injuries are separate diseases with certain shared pathologies that achieve a common end - cell death and human injury due to hypoxia, or lack of oxygen. [More]
HCV more common in West Africa yet lacks equal attention as HIV/AIDS or Ebola

HCV more common in West Africa yet lacks equal attention as HIV/AIDS or Ebola

More than 180 million people in the world have hepatitis C, compared with the 34 million with HIV/AIDS and the roughly 30,000 who have had Ebola. [More]
U of T's Marialena Mouzaki named Best International Abstract Awardee by A.S.P.E.N.

U of T's Marialena Mouzaki named Best International Abstract Awardee by A.S.P.E.N.

Marialena Mouzaki, MD, MSc, an assistant professor at University of Toronto and a staff gastroenterologist at Toronto's Hospital for Sick Children, has been named the Best International Abstract Awardee by the American Society for Parenteral and Enteral. The award is for her research on pediatric end-stage liver disease that she will present at A.S.P.E.N.'s Clinical Nutrition Week scientific conference in Long Beach, California, February 14 to 17. [More]
40% of prison and jail inmates have chronic medical problems, shows BJS survey

40% of prison and jail inmates have chronic medical problems, shows BJS survey

An estimated 40 percent of state and federal prisoners and jail inmates reported having a current chronic medical condition in the 2011–12 National Inmate Survey, the Bureau of Justice Statistics (BJS) announced today. [More]
Researchers develop new MRI-based technique to better detect NAFLD in children

Researchers develop new MRI-based technique to better detect NAFLD in children

Between 5 and 8 million children in the United States have nonalcoholic fatty liver disease (NAFLD), yet most cases go undiagnosed. To help address this issue, researchers at UC San Diego School of Medicine have developed a new magnetic resonance imaging (MRI)-based technique to help clinicians and researchers better detect and evaluate NAFLD in children. [More]
Chemotherapy or immunosuppressive treatment may reactivate HBV

Chemotherapy or immunosuppressive treatment may reactivate HBV

Individuals previously infected with the hepatitis B virus (HBV) who receive chemotherapy or immunosuppressive treatment may be at risk of reactivating the disease according to a summary of report from the Emerging Trends Conference, "Reactivation of Hepatitis B," and published in Hepatology, a journal of the American Association for the Study of Liver Diseases. [More]
AbbVie releases Phase 3 results from all-oral OBV/PTV/r treatment for GT1b chronic HCV infection

AbbVie releases Phase 3 results from all-oral OBV/PTV/r treatment for GT1b chronic HCV infection

AbbVie released top-line Phase 3 results for its investigational, all-oral, ribavirin (RBV)-free, two direct-acting antiviral treatment with ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) in patients with genotype 1b (GT1b) chronic hepatitis C virus (HCV) infection in Japan. [More]
Farnesoid-X receptor could play key role in hepatobiliary and gastrointestinal disorders

Farnesoid-X receptor could play key role in hepatobiliary and gastrointestinal disorders

The farnesoid-X receptor (FXR), also known as the chief regulator of bile acid metabolism, is thought to play a role in some hepatobiliary and gastrointestinal disorders. [More]
Age and HBsAg level predict NA-induced HBeAg seroconversion durability

Age and HBsAg level predict NA-induced HBeAg seroconversion durability

The combination of age and baseline hepatitis B s-antigen level can help predict hepatitis B virus relapse in patients who achieve hepatitis B e-antigen loss or seroconversion following nucleos(t)ide analogue (NA) treatment, researchers report. [More]